resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.
Our lead program focuses on mTOR, an evolutionarily conserved pathway that regulates aging, and specifically selective inhibition of the target of rapamycin complex 1 (TORC1).
- Our initial focus is developing RTB101, an orally administered, small molecule, potent TORC1 inhibitor alone or in combination with other mTOR inhibitors.
- Our first-in-class TORC1 immunotherapy approach is supported by a randomized, placebo-controlled Phase 2a study in 264 elderly subjects that provided statistically significant and clinically meaningful results.
- Our lead indication is the reduction of incidence of respiratory tract infections in the elderly at high risk of mortality and morbidity due to RTIs. RTIs are the fifth leading cause of death in people aged 85 and over and the seventh leading cause of death in people 65 and over. The majority of RTIs are causes by viruses for which there are no approved therapies.
- We believe TORC1 inhibition may have therapeutic benefit in multiple aging-related diseases.
Copyright West LLC. Minimum 15 minutes delayed.